Published April 2024
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
Read More
Clinical Resources
Position Statements
British Society of Gastroenterology and Association of Coloproctology of Great Britain and Ireland position on tranexamic acid in upper and lower gastrointestinal bleeding
clinical-resource/Tranexamic-acid-in-upper-lower-GI-bleeding
Following a concern raised to NHS England’s National Patient Safety Team regarding tranexamic acid use in gastrointestinal bleeding, and in light of the 2020 publication of the HALT-IT trial results,
Guidance
BSG Nurses Association
Endoscopy
BSG, ACPGBI and AUGIS guidance on the scope of professional practice for clinical endoscopists
clinical-resource/Guidance-on-practice-for-clinical-endoscopists
This document focuses on the scope of professional practice for clinical endoscopists (previously known as non- medical endoscopists/nurse endoscopists).